Role of telomerase in anticancer activity of pristimerin in prostate cancer cells
- PMID:26259389
Role of telomerase in anticancer activity of pristimerin in prostate cancer cells
Abstract
Pristimerin (PM) is a quinonemethide triterpenoid present in various plant species with strong antiprolifertive and proapoptotic activities in cancer cells. The effect of PM on telomerase which is reactivated in most cancers including carcinoma of the prostate (CaP) has not been studied. We investigated the effect of PM on the expression of human telomerase reverse transcriptase (hTERT) gene that codes for the catalytic subunit of the telomerase holoenzyme complex in prostate cancer cell lines LNCaP and PC-3 cells. The inhibition of cell proliferation and induction of apoptosis by PM in both cell lines was associated with the inhibition of hTERT mRNA expression, suppression of native and phosphorylated hTERT protein and hTERT telomerase activity. The ablation of hTERT expression increased the sensitivity of cancer cells to PM. In addition, results also revealed that the inhibition of hTERT expression is attributed to the inhibition of transcription factors SP1, c-Myc and STAT3 and protein kinase B/Akt which regulate hTERT transcriptionally and post-translationally, respectively. These data provide evidence that telomerase is a potential target of PM in prostate cancer.
Similar articles
- Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells.Deeb D, Gao X, Liu Y, Pindolia K, Gautam SC.Deeb D, et al.Oncol Rep. 2015 Jul;34(1):518-24. doi: 10.3892/or.2015.3989. Epub 2015 May 19.Oncol Rep. 2015.PMID:25997419Free PMC article.
- Telomerase reverse transcriptase (TERT) is a therapeutic target of oleanane triterpenoid CDDO-Me in prostate cancer.Liu Y, Gao X, Deeb D, Arbab AS, Gautam SC.Liu Y, et al.Molecules. 2012 Dec 11;17(12):14795-809. doi: 10.3390/molecules171214795.Molecules. 2012.PMID:23519253Free PMC article.
- Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.Jagadeesh S, Kyo S, Banerjee PP.Jagadeesh S, et al.Cancer Res. 2006 Feb 15;66(4):2107-15. doi: 10.1158/0008-5472.CAN-05-2494.Cancer Res. 2006.PMID:16489011
- Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review.Yousef BA, Hassan HM, Zhang LY, Jiang ZZ.Yousef BA, et al.Curr Cancer Drug Targets. 2017;17(2):100-108. doi: 10.2174/1568009616666160112105824.Curr Cancer Drug Targets. 2017.PMID:26758533Review.
- Targeting telomerase for its advent in cancer therapeutics.Bajaj S, Kumar MS, Peters GJ, Mayur YC.Bajaj S, et al.Med Res Rev. 2020 Sep;40(5):1871-1919. doi: 10.1002/med.21674. Epub 2020 May 11.Med Res Rev. 2020.PMID:32391613Review.
Cited by
- Effect ofAchillea wilhelmsii extract on expression of the human telomerase reverse transcriptase mRNA in the PC3 prostate cancer cell line.Ashtiani M, Nabatchian F, Galavi HR, Saravani R, Farajian-Mashhadi F, Salimi S.Ashtiani M, et al.Biomed Rep. 2017 Sep;7(3):251-256. doi: 10.3892/br.2017.956. Epub 2017 Jul 31.Biomed Rep. 2017.PMID:28811896Free PMC article.
- The cellular senescence of leukemia-initiating cells from acute lymphoblastic leukemia is postponed by β-Arrestin1 binding with P300-Sp1 to regulate hTERT transcription.Liu S, Liu H, Qin R, Shu Y, Liu Z, Zhang P, Duan C, Hong D, Yu J, Zou L.Liu S, et al.Cell Death Dis. 2017 Apr 20;8(4):e2756. doi: 10.1038/cddis.2017.164.Cell Death Dis. 2017.PMID:28425985Free PMC article.
- Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances.Chen RZ, Yang F, Zhang M, Sun ZG, Zhang N.Chen RZ, et al.Front Oncol. 2021 May 7;11:671548. doi: 10.3389/fonc.2021.671548. eCollection 2021.Front Oncol. 2021.PMID:34026649Free PMC article.Review.
- Terpenoids, Cannabimimetic Ligands, beyond theCannabis Plant.Gonçalves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC.Gonçalves ECD, et al.Molecules. 2020 Mar 29;25(7):1567. doi: 10.3390/molecules25071567.Molecules. 2020.PMID:32235333Free PMC article.Review.
- Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies.Prabhu KS, Jessy S, Kuttikrishnan S, Mujeeb F, Mariyam Z, Habeeba U, Ahmad N, Bhat AA, Uddin S.Prabhu KS, et al.Pharmaceuticals (Basel). 2024 Apr 30;17(5):578. doi: 10.3390/ph17050578.Pharmaceuticals (Basel). 2024.PMID:38794148Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Medical
Miscellaneous